@article{Parra_Lindarte_Rubio_2020, title={Over optimum response to PCSK-9 inhibitors: ¿is it mandatory to supply them every 2 weeks?, about a case}, volume={7}, url={https://revistaendocrino.org/index.php/rcedm/article/view/568}, DOI={10.53853/encr.7.1.568}, abstractNote={<p>The PCSK-9 inhibitors are presented as an excellent alternative treatment in those cases of hypercholesterolemia that do not reach goals with high intensity statin treatment and ezetimibe, additionally in patients with statin intolerance who need to have LDL cholesterol goals. In this case we expose the possibility to treat to target LDL goals and use PCSK-9i later than 2 weeks.</p>}, number={1}, journal={Revista Colombiana de Endocrinología, Diabetes & Metabolismo}, author={Parra, G. A. and Lindarte, H. H. and Rubio, A. F.}, year={2020}, month={Apr.}, pages={43–44} }